Heyman M R, Flores R H, Edelman B B, Carliner N H
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.
South Med J. 1988 Jul;81(7):934-6. doi: 10.1097/00007611-198807000-00035.
The lupus anticoagulant, with or without other symptoms or signs of lupus, has been described in patients taking procainamide. Screening all such patients for the presence of these anticoagulants may be warranted (despite the rarity of episodes of bleeding) in view of the potentially increased risk of thrombotic events in patients who may already be predisposed. A prospective study to determine the incidence of lupus anticoagulant in procainamide-treated patients and the true frequency of thrombosis in these patients would be helpful in determining appropriate management.
服用普鲁卡因胺的患者中曾有狼疮抗凝物（无论有无其他狼疮症状或体征）的相关报道。鉴于可能已存在易患倾向的患者发生血栓事件的风险潜在增加，对所有此类患者筛查这些抗凝物的存在情况可能是必要的（尽管出血事件罕见）。一项前瞻性研究，以确定接受普鲁卡因胺治疗的患者中狼疮抗凝物的发生率以及这些患者中血栓形成的实际频率，将有助于确定适当的管理措施。
